We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Discusses Use of Adult Data to Support Pediatric Device Use

FDA Discusses Use of Adult Data to Support Pediatric Device Use

May 8, 2015

Devicemakers looking to market their products for use in children based on adult clinical trials should limit their use of that data to situations in which the course of the disease or condition and the device’s effects are “sufficiently similar” in both populations, the U.S. FDA says.

Partial data extrapolation, combined through a statistical model with pediatric data sources to demonstrate a reasonable assurance of effectiveness, is preferred over full extrapolation of data from adult studies, the agency says in draft guidance published Wednesday.

The guidance addresses the use of adult clinical trial data to increase the availability of devices for pediatric patients. It also discusses how devices should be labeled to support their safe and effective use in patients 21 and younger.

The FDA lists three main factors for partial extrapolation of data: the similarity of the existing adult response data and/or population characteristics to the intended pediatric population; the quality of the adult data; and whether the data can be used fairly and responsibly to determine the safety and effectiveness of the device.

Dealing With Uncertainty

The FDA cautions devicemakers that using extrapolated data adds a degree of uncertainty to safety and effectiveness assessments. The extent of that uncertainty depends on the differences between adult and pediatric patients and the quality of the data. Manufacturers should consult the FDA’s benefit-risk guidance to understand how the agency weighs extrapolated data during the course of premarket reviews, the guidance says.

The guidance is intended to address the pitfalls sponsors often face with pediatric trials. Among these are small and scattered populations leading to small trial sizes, challenges in enrollment and consent procedures and variations in physiology, anatomy and human factors in pediatric patients.

Comments are due Aug. 4 to docket no. 2015-10482. Read the draft guidance, Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices, at www.fdanews.com/05-11-15-pediatric-device.pdf. — John Bechtel

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing